Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer
Objectives:

To evaluate the safety and effectiveness of cell therapy using precision cells to treat Advanced Lung Cancer.

Eligibility:

Individuals greater than or equal to 18 years of age and less than or equal to 65 years of age who have been diagnosed with Advanced Lung Cancer.
Precision Cells|Chemotherapy|Advanced Lung Cancer
DRUG: Chemotherapy|BIOLOGICAL: precision cells
Overall survival, 2 years|Progress-free survival, 2 years
Quality of life, Questionnaire will be used., 2 years
A total of 40 patients may be enrolled over a period of 1-2 years.